AmpliMed, NeXstar deal

NXTR acquired the patent rights for MiKasome, a liposomal formulation of amikacin, from AmpliMed (Tuscon, Ariz.) for an undisclosed amount. NXTR, which is developing the drug to treat multidrug resistance in tuberculosis, said it wanted to own the product outright based on encouraging preclinical data.

Concurrently, NXTR (Boulder, Colo.) reduced its ownership in AmpliMed to 19.9 percent from 60 percent. AmpliMed owned the patents as a result of a 1990 agreement with Vestar Inc., which merged with NXTR in 1994. ...